Aprea Therapeutics approved to transfer stock listing from Nasdaq Global Select to Capital Market on July 6

Aprea Therapeutics, Inc.

Received Nasdaq approval on July 3, 2023 to transfer listing from Global Select to Capital Market.
Transfer becomes effective at the opening of business on July 6, 2023.
Aprea's common stock (APRE) will continue trading on the Nasdaq Capital Market.

item 3.01

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-078072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.